ReviewWorld journal of gastroenterology2022
Anabolic androgenic steroid-induced liver injury: An update.
Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Biochemical liver damage during gender affirming therapy in trans adults assigned female at birth: a meta-analysis.Journal of endocrinological investigation · 2025Pooled it
- Testosterone abuse in Brazil: a growing public health challenge.Clinics (Sao Paulo, Brazil) · 2026Article
- Article
- Article
- Health consequences of anabolic steroids: a sexual-medicine perspective.International journal of impotence research · 2026Review
- A Star-PEGylation Strategy to Improve Testosterone Pharmacokinetics.Molecules (Basel, Switzerland) · 2026Article
- Confidence in Managing Use and Minimising Harm as Mediators of Quality of Life among Anabolic-Androgenic Steroid Consumers in Alcohol and Other Drug Treatment Settings.European addiction research · 2026Article
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026Review
- A guide to healthcare maintenance for the patient with inflammatory bowel disease.Annals of gastroenterology · 2026Review
- Non-medical use of exogenous testosterone and anabolic-androgenic substances in young men: health, psychological, and fertility consequences.Frontiers in endocrinology · 2026Review
- The effect of training andAvicenna journal of phytomedicine · 2026Article
- Effects of Methandienone on the ovaries of rabbits in relation to the aromatase gene (CYP19A1) and oxidative markers and the possible protective role of selenium.F1000Research · 2026Article
- Treatment of Symptomatic Male Hypogonadism with New Oral Testosterone Therapies: A Comparative Review of Jatenzo, Tlando, and Kyzatrex.Medicines (Basel, Switzerland) · 2025Review
- Adulteration of Sports Supplements with Anabolic Steroids-From Innocent Athlete to Vicious Cheater.Nutrients · 2025Review
- Article
- Best Practice Guidance for Male Individuals Using Anabolic Androgenic Steroids in Recreational Sports Within Primary Care: Protocol for a Modified Delphi Consensus Study.JMIR research protocols · 2025Article
- Allograft Injury Following Nandrolone and High-Dose Dietary Supplements Use in a Liver Transplant Recipient: A Case Report.Clinical case reports · 2025Article
- Evaluation of implementing drug checking services for anabolic androgenic steroids in Switzerland: a pilot study.Harm reduction journal · 2025Article
- The 4Rs Framework of Sports Nutrition: An Update with Recommendations to Evaluate Allostatic Load in Athletes.Life (Basel, Switzerland) · 2025Review
- Predicting Anabolic Androgenic Steroid Doping among Specialized Health Care Patients with Elastic Net Regression Reveals Potential Laboratory Variables for "Patient Biological Passport".Sports medicine - open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anabolic androgenic steroids (AASs) are a group of molecules including endogenous testosterone and synthetic derivatives that have both androgenic and anabolic effects. These properties make them therapeutically beneficial in medical conditions such as hypogonadism. However, they are commonly bought illegally and misused for their anabolic, skeletal muscle building, and performance-enhancing effects. Supraphysiologic and long-term use of AASs affects all organs, leading to cardiovascular, neurological, endocrine, gastrointestinal, renal, and hematologic disorders. Hepatotoxicity is one of the major concerns regarding AASs treatment and abuse. Testosterone and its derivatives have been most often shown to induce a specific form of cholestasis, peliosis hepatis, and hepatic benign and malignant tumors. It is currently believed that mechanisms of pathogenesis of these disorders include disturbance of antioxidative factors, upregulation of bile acid synthesis, and induction of hepatocyte hyperplasia. Most toxicity cases are treated with supportive measures and liver function normalizes with discontinuation of AAS. However, some long-term consequences are irreversible. AAS-induced liver injury should be taken in consideration in patients with liver disorders, especially with the increasing unintentional ingestion of supplements containing AAS. In this paper, we review the most current knowledge about AAS-associated adverse effects on the liver, and their clinical presentations, prevalence, and pathophysiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.